Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for pediatric upper limb spasticity in cerebral palsy
2010-021817-22Phase 3Completed
- Sponsor
- Ipsen
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in upper extremity spasticity and cerebral palsy (CP) (3 arms), sponsored by Ipsen. Primary endpoint: Primary efficacy endpoint. Started Dec 2013; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
upper extremity spasticitycerebral palsy (CP)
Beyond the preview
Go deeper on 2010-021817-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021817-22.